bioAffinity Tech Financials
This page shows bioAffinity Tech (BIAFW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is carrying an asset-light but cash-burning operation whose overhead stayed high as FY2025 revenue slipped.
Cash rose to$6.4M and the current ratio improved to 2.6x, a clear rebound from the prior year's tighter liquidity. But FY2025 also included$14.7M of financing inflow against-$9.3M of operating cash burn, so the healthier balance-sheet posture was funding-driven rather than evidence the business had begun to self-finance.
Revenue fell to
Free cash flow of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of bioAffinity Tech's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
bioAffinity Tech passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, bioAffinity Tech generates $0.63 in operating cash flow (-$9.3M OCF vs -$14.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
bioAffinity Tech earns $-238.3 in operating income for every $1 of interest expense (-$10.6M vs $44K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
bioAffinity Tech generated $6.2M in revenue in fiscal year 2025. This represents a decrease of 34.2% from the prior year.
bioAffinity Tech's EBITDA was -$10.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.6% from the prior year.
bioAffinity Tech reported -$14.9M in net income in fiscal year 2025. This represents a decrease of 64.9% from the prior year.
Cash & Balance Sheet
bioAffinity Tech generated -$9.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 27.9% from the prior year.
bioAffinity Tech held $6.4M in cash against $0 in long-term debt as of fiscal year 2025.
bioAffinity Tech had 4M shares outstanding in fiscal year 2025.
Margins & Returns
bioAffinity Tech's operating margin was -171.6% in fiscal year 2025, reflecting core business profitability. This is down 75.9 percentage points from the prior year.
bioAffinity Tech's net profit margin was -242.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 145.4 percentage points from the prior year.
bioAffinity Tech's ROE was -204.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 142.5 percentage points from the prior year.
Capital Allocation
bioAffinity Tech invested $1.4M in research and development in fiscal year 2025. This represents a decrease of 5.3% from the prior year.
bioAffinity Tech invested $61K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 23.4% from the prior year.
BIAFW Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M-15.1% | $1.6M+10.1% | $1.4M+13.9% | $1.3M-31.5% | $1.9M-16.0% | $2.2M-6.1% | $2.4M-2.0% | $2.4M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $350K-6.5% | $374K+13.1% | $331K+6.2% | $311K-15.2% | $367K-6.0% | $391K+42.3% | $274K-31.8% | $402K |
| SG&A Expenses | $3.2M+6.7% | $3.0M+37.5% | $2.2M-0.2% | $2.2M-9.7% | $2.5M-16.0% | $2.9M+23.5% | $2.4M-4.4% | $2.5M |
| Operating Income | -$3.6M-15.3% | -$3.1M-36.8% | -$2.3M+8.9% | -$2.5M+4.2% | -$2.6M+10.8% | -$2.9M-49.3% | -$2.0M+5.5% | -$2.1M |
| Interest Expense | $15K+12.6% | $13K+143.9% | $5K-48.8% | $10K-32.5% | $15K-38.2% | $25K+15.8% | $22K-2.8% | $22K |
| Income Tax | N/A | $3K0.0% | $3K-89.0% | $29K+233.3% | $9K | $0-100.0% | $3K-52.8% | $5K |
| Net Income | -$3.6M-15.7% | -$3.1M+37.9% | -$5.1M-24.4% | -$4.1M-52.6% | -$2.7M+10.3% | -$3.0M-48.3% | -$2.0M+5.2% | -$2.1M |
| EPS (Diluted) | $-0.81 | N/A | $-4.74 | $-0.17+96.5% | $-4.80 | N/A | $-4.84-2447.4% | $-0.19 |
BIAFW Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.9M-27.5% | $11.0M-5.1% | $11.5M+143.0% | $4.8M-14.4% | $5.5M-14.8% | $6.5M-0.6% | $6.6M-1.6% | $6.7M |
| Current Assets | $4.3M-42.6% | $7.6M-12.2% | $8.6M+416.1% | $1.7M-10.5% | $1.9M-30.8% | $2.7M+5.7% | $2.5M-4.9% | $2.7M |
| Cash & Equivalents | $3.1M-52.0% | $6.4M-15.9% | $7.7M+855.3% | $803K+80.5% | $445K-59.8% | $1.1M+46.1% | $757K-5.6% | $801K |
| Inventory | $78K+45.5% | $54K+52.0% | $35K-19.9% | $44K+13.4% | $39K+40.5% | $28K+8.9% | $25K-14.8% | $30K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M |
| Total Liabilities | $4.3M+16.3% | $3.7M+39.3% | $2.6M-61.6% | $6.9M+67.7% | $4.1M+5.0% | $3.9M+14.0% | $3.4M+6.4% | $3.2M |
| Current Liabilities | $3.2M+9.6% | $2.9M+23.2% | $2.4M-8.8% | $2.6M-24.2% | $3.4M+10.0% | $3.1M+24.6% | $2.5M+7.1% | $2.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $3.7M-49.7% | $7.3M-18.2% | $8.9M+516.7% | -$2.1M-248.4% | $1.4M-44.7% | $2.6M-16.6% | $3.1M-9.1% | $3.4M |
| Retained Earnings | -$72.2M-5.3% | -$68.6M-4.8% | -$65.4M-8.4% | -$60.4M-7.2% | -$56.3M-5.0% | -$53.6M-5.9% | -$50.7M-4.1% | -$48.7M |
BIAFW Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2M-26.1% | -$2.6M-3.2% | -$2.5M+6.3% | -$2.6M-61.2% | -$1.6M+2.1% | -$1.7M+1.9% | -$1.7M-11.5% | -$1.5M |
| Capital Expenditures | $6K+566200.0% | $1+100.0% | -$4K-127.2% | $13K-73.6% | $51K+5078500.0% | $1-100.0% | $9K-66.7% | $28K |
| Free Cash Flow | -$3.2M-26.3% | -$2.6M-3.0% | -$2.5M+6.6% | -$2.7M-57.2% | -$1.7M-0.9% | -$1.7M+2.4% | -$1.7M-10.1% | -$1.6M |
| Investing Cash Flow | -$6K-566200.0% | -$1-100.0% | $4K+127.2% | -$13K+73.6% | -$51K-5078500.0% | -$1+100.0% | -$9K+66.7% | -$28K |
| Financing Cash Flow | -$119K-108.8% | $1.3M-85.7% | $9.3M+209.5% | $3.0M+192.5% | $1.0M-49.1% | $2.0M+21.0% | $1.7M+1936.6% | -$91K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BIAFW Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -267.6%-70.7pp | -196.9%-38.4pp | -158.6%+39.6pp | -198.2%-56.4pp | -141.7%-8.3pp | -133.5%-49.5pp | -84.0%+3.1pp | -87.1% |
| Net Margin | -268.6%-71.7pp | -197.0%+152.3pp | -349.3%-29.4pp | -319.9%-176.3pp | -143.5%-9.1pp | -134.4%-49.3pp | -85.1%+2.9pp | -88.0% |
| Return on Equity | -99.2%-56.0pp | -43.1%+13.6pp | -56.7% | N/A | -184.8%-70.8pp | -114.0%-49.9pp | -64.1%-2.6pp | -61.5% |
| Return on Assets | -45.7%-17.1pp | -28.6%+15.1pp | -43.8%+41.7pp | -85.5%-37.5pp | -48.0%-2.4pp | -45.6%-15.0pp | -30.5%+1.2pp | -31.7% |
| Current Ratio | 1.36-1.2 | 2.60-1.0 | 3.65+3.0 | 0.64+0.1 | 0.55-0.3 | 0.87-0.2 | 1.02-0.1 | 1.15 |
| Debt-to-Equity | 1.17+0.7 | 0.51+0.2 | 0.30+3.5 | -3.22-6.1 | 2.85+1.4 | 1.50+0.4 | 1.10+0.2 | 0.94 |
| FCF Margin | -239.2%-78.5pp | -160.7%+11.1pp | -171.8%+37.8pp | -209.6%-118.3pp | -91.3%-15.3pp | -76.0%-2.9pp | -73.1%-8.0pp | -65.1% |
Similar Companies
Frequently Asked Questions
What is bioAffinity Tech's annual revenue?
bioAffinity Tech (BIAFW) reported $6.2M in total revenue for fiscal year 2025. This represents a -34.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is bioAffinity Tech's revenue growing?
bioAffinity Tech (BIAFW) revenue declined by 34.2% year-over-year, from $9.4M to $6.2M in fiscal year 2025.
Is bioAffinity Tech profitable?
No, bioAffinity Tech (BIAFW) reported a net income of -$14.9M in fiscal year 2025, with a net profit margin of -242.0%.
What is bioAffinity Tech's EBITDA?
bioAffinity Tech (BIAFW) had EBITDA of -$10.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is bioAffinity Tech's operating margin?
bioAffinity Tech (BIAFW) had an operating margin of -171.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is bioAffinity Tech's net profit margin?
bioAffinity Tech (BIAFW) had a net profit margin of -242.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is bioAffinity Tech's return on equity (ROE)?
bioAffinity Tech (BIAFW) has a return on equity of -204.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is bioAffinity Tech's free cash flow?
bioAffinity Tech (BIAFW) generated -$9.4M in free cash flow during fiscal year 2025. This represents a -27.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is bioAffinity Tech's operating cash flow?
bioAffinity Tech (BIAFW) generated -$9.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are bioAffinity Tech's total assets?
bioAffinity Tech (BIAFW) had $11.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are bioAffinity Tech's capital expenditures?
bioAffinity Tech (BIAFW) invested $61K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does bioAffinity Tech spend on research and development?
bioAffinity Tech (BIAFW) invested $1.4M in research and development during fiscal year 2025.
What is bioAffinity Tech's current ratio?
bioAffinity Tech (BIAFW) had a current ratio of 2.60 as of fiscal year 2025, which is generally considered healthy.
What is bioAffinity Tech's debt-to-equity ratio?
bioAffinity Tech (BIAFW) had a debt-to-equity ratio of 0.51 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is bioAffinity Tech's return on assets (ROA)?
bioAffinity Tech (BIAFW) had a return on assets of -136.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is bioAffinity Tech's cash runway?
Based on fiscal year 2025 data, bioAffinity Tech (BIAFW) had $6.4M in cash against an annual operating cash burn of $9.3M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is bioAffinity Tech's Piotroski F-Score?
bioAffinity Tech (BIAFW) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are bioAffinity Tech's earnings high quality?
bioAffinity Tech (BIAFW) has an earnings quality ratio of 0.63x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can bioAffinity Tech cover its interest payments?
bioAffinity Tech (BIAFW) has an interest coverage ratio of -238.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is bioAffinity Tech?
bioAffinity Tech (BIAFW) scores 49 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.